
Conexeu Sciences Targets Aesthetic Gap Created by GLP-1 Weight Loss
As the weight-loss drug market barrels toward a $190 billion valuation by 2035, a secondary medical crisis has emerged: rapid facial and body volume loss that legacy aesthetic treatments were never designed to address. Conexeu Sciences is now positioning its preclinical CXU platform to bridge this specific tissue-restoration void.


























